Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chmielecki, Juliann, Foo, Jasmine, Oxnard, Geoffrey R., Hutchinson, Katherine, Ohashi, Kadoaki, Somwar, Romel, Wang, Lu, Amato, Katherine R., Arcila, Maria, Sos, Martin L., Socci, Nicholas D., Viale, Agnes, de Stanchina, Elisa, Ginsberg, Michelle S., Thomas, Roman K., Kris, Mark G., Inoue, Akira, Ladanyi, Marc, Miller, Vincent A., Michor, Franziska, Pao, William
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500629/
https://ncbi.nlm.nih.gov/pubmed/21734175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3002356
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars